Regent Peak Wealth Advisors LLC Makes New $1.35 Million Investment in AbbVie Inc. $ABBV

Regent Peak Wealth Advisors LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,829 shares of the company’s stock, valued at approximately $1,350,000.

Other institutional investors also recently modified their holdings of the company. Ellenbecker Investment Group increased its stake in AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after purchasing an additional 44 shares in the last quarter. Security National Bank of Sioux City Iowa IA lifted its stake in shares of AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after buying an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC grew its holdings in shares of AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after buying an additional 45 shares during the last quarter. Hobart Private Capital LLC increased its position in shares of AbbVie by 4.4% during the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock worth $261,000 after acquiring an additional 48 shares in the last quarter. Finally, Rise Advisors LLC increased its position in shares of AbbVie by 3.4% during the third quarter. Rise Advisors LLC now owns 1,451 shares of the company’s stock worth $336,000 after acquiring an additional 48 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of AbbVie stock opened at $230.07 on Friday. The business’s fifty day simple moving average is $226.73 and its 200 day simple moving average is $212.41. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a market capitalization of $406.63 billion, a P/E ratio of 174.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is presently 496.97%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ABBV shares. UBS Group raised their price target on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Morgan Stanley raised their target price on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. BMO Capital Markets increased their price target on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research report on Friday, September 12th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $245.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.